Pricing and reimbursement of orphan drugs in Italy

被引:0
|
作者
Lopatriello, S.
Schivazappa, C.
Negrini, C.
Berto, P.
机构
[1] PBE Consulting, Verona, Italy
[2] PBE Consulting, Milan, Italy
关键词
D O I
10.1016/S1098-3015(10)63221-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
引用
下载
收藏
页码:A208 / A209
页数:2
相关论文
共 50 条
  • [1] PRICING AND REIMBURSEMENT OF ORPHAN DRUGS IN CANADA
    Kumar, J.
    Bachman, E. M.
    VALUE IN HEALTH, 2011, 14 (03) : A29 - A29
  • [2] REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
    Cheng, C. Y.
    Chan, H. W.
    Fang, C. H.
    VALUE IN HEALTH, 2019, 22 : S856 - S856
  • [3] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [4] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
  • [5] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [6] PRICING AND REIMBURSEMENT SYSTEM OF ORPHAN DRUGS IN THE CZECH REPUBLIC
    Prochazkova, M.
    Kubickova, P.
    Mazelova, J.
    Hambalek, J.
    Heislerova, M.
    VALUE IN HEALTH, 2013, 16 (07) : A474 - A474
  • [7] INITIATIVES THAT IMPACT PRICING AND REIMBURSEMENT OF ORPHAN (AND ULTRA ORPHAN) DRUGS: REVIEW OF EUROPEAN TRENDS
    Rousseau, B.
    Poinas, A.
    Oliver, L.
    Collings, H.
    VALUE IN HEALTH, 2017, 20 (09) : A695 - A696
  • [8] EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION MAKING FOR ORPHAN DRUGS IN ASIA
    Tan, S.
    Dummett, H.
    Kirpekar, S.
    Guan, Q.
    Priest, V. L.
    VALUE IN HEALTH, 2012, 15 (07) : A621 - A622
  • [9] HEALTH TECHNOLOGY ASSESSMENT, PRICE AND REIMBURSEMENT REVIEW FOR ORPHAN DRUGS IN ITALY
    Tavella, F.
    Korchagina, D.
    Rodrigues, J.
    Remuzat, C.
    VALUE IN HEALTH, 2014, 17 (07) : A540 - A540